Treatment Options for Knee Osteoarthritis Flare-Ups

Topical capsaicin is recommended by NICE as a treatment option for knee and hand osteoarthritis. Although there is limited data on its efficacy for hand arthritis, NICE believes that its effectiveness for knee osteoarthritis can be extrapolated. Capsaicin is a safe and easy-to-use topical treatment that promotes self-management of flare-ups, making it a good option for patients who cannot tolerate oral NSAIDs. It can be used in conjunction with existing oral medications.

While opioid analgesia in the form of a buprenorphine patch is also an option, it may not be appropriate for patients who are currently taking oral paracetamol and PRN ibuprofen. Additionally, buprenorphine patches are associated with skin reactions in 40% of patients and lack flexibility in managing flare-ups. Copper bracelets, lidocaine patches, and topical rubefacients are not recommended for the management of osteoarthritis symptoms. Patients should be counseled to watch for early signs of sensitivity to topical preparations and to discontinue use if necessary.

If simple analgesia with paracetamol and NSAIDs is not effective in treating endometriosis symptoms, hormonal treatment with the combined oral contraceptive pill or a progestogen should be considered.

Although a referral to gynaecology may be necessary due to the recurrence of symptoms and potential pelvic/bowel involvement, primary care can offer further treatment options in the meantime. Hormonal treatment is recommended for this patient, and the combined oral contraceptive pill or any progestogen options can be considered. As the patient plans to start a family soon, a hormonal option that can be quickly reversed is preferred.

Buscopan is not an appropriate treatment for endometriosis. While it may provide some relief for pelvic symptoms during menstruation, it is not a treatment for the condition. It may be used to alleviate cramps associated with irritable bowel syndrome.

Injectable depo-provera is not the best option for this patient as it may delay the return of fertility, which conflicts with her desire to start a family soon.

Opioid analgesia is not recommended for endometriosis treatment as it carries the risk of side effects and dependence. It is not a suitable long-term solution for managing symptoms.

Endometriosis is a condition where endometrial tissue grows outside of the uterus, affecting around 10% of women of reproductive age. Symptoms include chronic pelvic pain, painful periods, pain during sex, and subfertility. Diagnosis is made through laparoscopy, and treatment depends on the severity of symptoms. First-line treatments include NSAIDs and hormonal treatments such as the combined oral contraceptive pill or progestogens. If these do not improve symptoms or fertility is a priority, referral to secondary care may be necessary. Treatment options in secondary care include GnRH analogues and surgery, with laparoscopic excision or ablation of endometriosis plus adhesiolysis recommended for women trying to conceive. Ovarian cystectomy may also be necessary for endometriomas.

Understanding Acute Epididymo-orchitis: Symptoms, Diagnosis, and Differential Diagnosis

Acute epididymo-orchitis is a condition characterized by pain, swelling, and inflammation of the epididymis, with or without inflammation of the testes. This condition is commonly caused by infections that spread from the urethra or bladder. While orchitis, which is an infection limited to the testis, is less common, epididymitis usually presents with unilateral scrotal pain and swelling of relatively acute onset.

Aside from the symptoms of urethritis or a urinary infection, tenderness and swelling of the epididymis may start at the tail at the lower pole of the testis and spread towards the head at the upper pole of the testis, with or without involvement of the testis. There may also be a secondary hydrocele, erythema, and/or edema of the scrotum on the affected side, as well as pyrexia.

To diagnose epididymo-orchitis, Prehn’s sign is often used, which is indicative of epididymitis. Scrotal elevation relieves pain in epididymitis but not torsion. However, if there is any doubt, urgent referral is indicated, as torsion is the most important differential diagnosis. Torsion is more likely if the onset of pain is more acute and the pain is severe.

It is important to note that a painful swollen testicle in an adolescent boy or a young man should be regarded as torsion until proven otherwise. In this case, the testis is said to be normal in size. Testicular cancer, on the other hand, is usually painless, and there is usually swelling of the testis. Hydrocele causes scrotal swelling.

In summary, understanding the symptoms, diagnosis, and differential diagnosis of acute epididymo-orchitis is crucial in providing appropriate and timely medical care.

A labial lump and inguinal lymphadenopathy in an older woman may indicate the presence of vulval carcinoma, as these symptoms are concerning and should not be ignored. Although labial lumps are not uncommon, it is important to be vigilant and seek medical attention if a new lump appears.

Understanding Vulval Carcinoma

Vulval carcinoma is a type of cancer that affects the vulva, which is the external female genitalia. It is a relatively rare condition, with only around 1,200 cases diagnosed in the UK each year. The majority of cases occur in women over the age of 65 years, and the most common type of vulval cancer is squamous cell carcinoma, accounting for around 80% of cases.

There are several risk factors associated with vulval carcinoma, including human papillomavirus (HPV) infection, vulval intraepithelial neoplasia (VIN), immunosuppression, and lichen sclerosus. Symptoms of vulval carcinoma may include a lump or ulcer on the labia majora, inguinal lymphadenopathy, and itching or irritation.

For this woman with symptomatic hypothyroidism requiring thyroxine replacement, the recommended starting dose according to BNF guidelines is 50-100 mcg once daily for patients under 50 years old. Additionally, clinical studies have demonstrated that an initial treatment dose of 1.6mcg/kg/day is appropriate for younger patients without heart disease. Therefore, the answer aligns with both the BNF recommendations and relevant research findings.

Managing Hypothyroidism: Dosage, Goals, and Side-Effects

Hypothyroidism is a condition where the thyroid gland doesn’t produce enough thyroid hormone. The management of hypothyroidism involves the use of levothyroxine, a synthetic form of thyroid hormone. The initial starting dose of levothyroxine should be lower in elderly patients and those with ischaemic heart disease. For patients with cardiac disease, severe hypothyroidism, or patients over 50 years, the initial starting dose should be 25 mcg od with dose slowly titrated. Other patients should be started on a dose of 50-100 mcg od. After a change in thyroxine dose, thyroid function tests should be checked after 8-12 weeks. The therapeutic goal is to achieve a ‘normalisation’ of the thyroid stimulating hormone (TSH) level, with a TSH value of 0.5-2.5 mU/l being the preferred range.

Women with established hypothyroidism who become pregnant should have their dose increased ‘by at least 25-50 micrograms levothyroxine’* due to the increased demands of pregnancy. The TSH should be monitored carefully, aiming for a low-normal value. There is no evidence to support combination therapy with levothyroxine and liothyronine.

Levothyroxine therapy may cause side-effects such as hyperthyroidism due to over-treatment, reduced bone mineral density, worsening of angina, and atrial fibrillation. Interactions with iron and calcium carbonate may reduce the absorption of levothyroxine, so they should be given at least 4 hours apart.

In summary, the management of hypothyroidism involves careful dosage adjustment, regular monitoring of thyroid function tests, and aiming for a TSH value in the normal range. Women who become pregnant should have their dose increased, and combination therapy with levothyroxine and liothyronine is not recommended. Patients should also be aware of potential side-effects and interactions with other medications.

*source: NICE Clinical Knowledge Summaries

Since the topical preparation did not work for the patient, the next step would be to try an oral antibiotic. The recommended first-line options are lymecycline, oxytetracycline, tetracycline, or doxycycline. Lymecycline is preferred as it only needs to be taken once a day, which can improve the patient’s adherence to the treatment.

Acne vulgaris is a common skin condition that usually affects teenagers and is characterized by the obstruction of hair follicles with keratin plugs, resulting in comedones, inflammation, and pustules. The severity of acne can be classified as mild, moderate, or severe, depending on the number and type of lesions present. Treatment for acne typically involves a step-up approach, starting with single topical therapy and progressing to combination therapy or oral antibiotics if necessary. Tetracyclines are commonly used but should be avoided in certain populations, and a topical retinoid or benzoyl peroxide should always be co-prescribed to reduce the risk of antibiotic resistance. Combined oral contraceptives can also be used in women, and oral isotretinoin is reserved for severe cases under specialist supervision. Dietary modification has no role in the management of acne.

When it comes to treating less severe depression, the recommended first-line antidepressant is an SSRI (selective serotonin reuptake inhibitor) like sertraline. Tricyclic antidepressants (TCAs) such as amitriptyline are no longer considered the first choice due to their increased risk of overdose. Monoamine oxidase inhibitors (MAOIs) like isocarboxazid are rarely prescribed due to their potential for serious side effects. Noradrenaline and specific serotonergic antidepressants (NASSAs) like mirtazapine may be an alternative for those who cannot take SSRIs, but they may cause more drowsiness.

NICE Guidelines for Managing Depression

The National Institute for Health and Care Excellence (NICE) has updated its guidelines for managing depression in 2022. The new guidelines classify depression severity as less severe and more severe based on a PHQ-9 score of <16 and ≥16, respectively. For less severe depression, NICE recommends discussing treatment options with patients and considering the least intrusive and least resource-intensive treatment first. Antidepressant medication should not be routinely offered as first-line treatment unless it is the patient's preference. Treatment options for less severe depression include guided self-help, group cognitive behavioral therapy (CBT), group behavioral activation (BA), individual CBT, individual BA, group exercise, group mindfulness and meditation, interpersonal psychotherapy (IPT), selective serotonin reuptake inhibitors (SSRIs), counseling, and short-term psychodynamic psychotherapy (STPP). For more severe depression, a shared decision should be made between the patient and healthcare provider. Treatment options for more severe depression include a combination of individual CBT and an antidepressant, individual CBT, individual BA, antidepressant medication (SSRI, SNRI, or another antidepressant if indicated based on previous clinical and treatment history), individual problem-solving, counseling, STPP, IPT, guided self-help, and group exercise.

The risk of Down’s syndrome is 1 in 1,000 at the age of 30, and this risk decreases by a factor of 3 for every 5 years.

Down’s Syndrome: Epidemiology and Genetics

Down’s syndrome is a genetic disorder that is caused by the presence of an extra copy of chromosome 21. The risk of having a child with Down’s syndrome increases with maternal age, with a 1 in 1,500 chance at age 20 and a 1 in 50 or greater chance at age 45. This can be remembered by dividing the denominator by 3 for every extra 5 years of age starting at 1/1,000 at age 30.

There are three main types of Down’s syndrome: nondisjunction, Robertsonian translocation, and mosaicism. Nondisjunction accounts for 94% of cases and occurs when the chromosomes fail to separate properly during cell division. Robertsonian translocation, which usually involves chromosome 14, accounts for 5% of cases and occurs when a piece of chromosome 21 attaches to another chromosome. Mosaicism, which accounts for 1% of cases, occurs when there are two genetically different populations of cells in the body.

The risk of recurrence for Down’s syndrome varies depending on the type of genetic abnormality. If the trisomy 21 is a result of nondisjunction, the chance of having another child with Down’s syndrome is approximately 1 in 100 if the mother is less than 35 years old. If the trisomy 21 is a result of Robertsonian translocation, the risk is much higher, with a 10-15% chance if the mother is a carrier and a 2.5% chance if the father is a carrier.

Lower gastrointestinal tract investigation should be conducted on any patient in this age group who has an unexplained microcytic anaemia to rule out the possibility of colorectal cancer.

Colorectal cancer referral guidelines were updated by NICE in 2015. Patients who are 40 years or older with unexplained weight loss and abdominal pain, those who are 50 years or older with unexplained rectal bleeding, and those who are 60 years or older with iron deficiency anaemia or a change in bowel habit should be referred urgently to colorectal services for investigation. Additionally, patients with positive results for occult blood in their faeces should also be referred urgently.

An urgent referral should be considered if there is a rectal or abdominal mass, an unexplained anal mass or anal ulceration, or if patients under 50 years old have rectal bleeding and any of the following unexplained symptoms or findings: abdominal pain, change in bowel habit, weight loss, or iron deficiency anaemia.

The NHS offers a national screening programme for colorectal cancer every two years to all men and women aged 60 to 74 years in England and 50 to 74 years in Scotland. Patients aged over 74 years may request screening. Eligible patients are sent Faecal Immunochemical Test (FIT) tests through the post. FIT is a type of faecal occult blood test that uses antibodies to detect and quantify the amount of human blood in a single stool sample. Patients with abnormal results are offered a colonoscopy.

The FIT test is also recommended for patients with new symptoms who do not meet the 2-week criteria listed above. For example, patients who are 50 years or older with unexplained abdominal pain or weight loss, those under 60 years old with changes in their bowel habit or iron deficiency anaemia, and those who are 60 years or older who have anaemia even in the absence of iron deficiency.

Understanding Drug-Eluting Stents and Antiplatelet Therapy for Coronary Stents

Drug-eluting stents (DESs) are metal stents coated with a growth-inhibiting agent that reduces the frequency of restenosis by about 50%. However, the reformation of endothelium is slowed, which prolongs the risk of thrombosis. DESs are recommended if the artery to be treated has a calibre < 3 mm or the lesion is longer than 15 mm, and the price difference between DESs and bare metal stents (BMSs) is no more than £300. Antiplatelet therapy with aspirin and clopidogrel is required for patients with coronary stents to reduce stent thrombosis. Aspirin is continued indefinitely, while clopidogrel should be used for at least one month with a BMS (ideally, up to one year), and for at least 12 months with a DES. It is important for cardiologists to explain this information to patients, but General Practitioners should also have some knowledge of these procedures. Understanding Drug-Eluting Stents and Antiplatelet Therapy for Coronary Stents